Clinic
Molecular Diagnostics Laboratory
Molecular Diagnostics Laboratory was paid $576K by Medicaid between Oct 2018 and May 2019, across 13 billing codes. Its largest line is 87798, Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism — 35% of everything it billed.
33Billing provider infoMOLECULAR DIAGNOSTICS LABORATORY
BIRMINGHAM, AL 35209
BIRMINGHAM, AL 35209
33aNPI1841799764assigned 02/06/2018
33bProvider typeHealth Service Clinic/Center
28Total paid$576K
24GClaims6,825
24DCodes billed13
24AFirst – last monthOct 2018 – May 2019
Compared with peers
Next to other Health Service Clinic/Center providers in Alabama
Rank by total paid#4 of 13
Median peer was paid$210K
This provider vs. median2.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,522 | $117K | |
| 2019 | 5,303 | $459K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 35% | 792 | 753 | $201K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 23% | 678 | 664 | $133K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 17% | 747 | 695 | $99K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 6.6% | 717 | 692 | $38K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 5.6% | 719 | 694 | $32K |
| 87149 | 3.1% | 790 | 752 | $18K | |
| 87561 | 3.0% | 678 | 664 | $18K | |
| 87581 | 3.0% | 678 | 664 | $18K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 2.2% | 479 | 470 | $13K |
| 87507 | <1% | 22 | 21 | $4K | |
| 87147 | <1% | 478 | 469 | $2K | |
| 87498 | <1% | 22 | 21 | $462.00 |
1 more codes
| 87187 | 0% | 25 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBLACK, ROBERT (MANAGING MEMBER)